research use only

Fluoxetine HCl 5-HT Receptor inhibitor

Name: Fluoxetine HCl
Brand: Selleck Chemicals
SKU: S1333
Availability: InStock
Rating: 5 (22 reviews)

Cat.No.S1333

Fluoxetine HCl is a selective serotonin-reuptake inhibitor (SSRI) at the neuronal membrane, used in the treatment of depression.

Chemical Structure

Molecular Weight: 345.79

Jump to

Quality Control

Batch: Purity: 99.94%

99.94

Related Targets	Adrenergic Receptor AChR COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR
Other 5-HT Receptor Inhibitors	WAY-100635 Maleate Puerarin Serotonin (5-HT) HCl SB269970 HCl Ketanserin BRL-15572 Dihydrochloride Nuciferine RS-127445 Flopropione Azacyclonol

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
HEK293	Function assay	30 mins	Inhibition of human SERT expressed in HEK293 cells assessed as inhibition of serotonin reuptake after 30 mins by fluorescence assay, IC50=0.15μM	22938049
HEK293	Function assay	30 mins	Inhibition of human NET expressed in HEK293 cells assessed as inhibition of noradrenaline reuptake after 30 mins by fluorescence assay, IC50=4.41μM	22938049
HEK293	Function assay	30 mins	Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake after 30 mins by fluorescence assay, IC50=18.4μM	22938049
mammalian cells	Function assay		Inhibition of human Potassium channel HERG expressed in mammalian cells, IC50=1.51356μM	12873512
JAR	Function assay		Inhibition concentration against [3H]5-HT uptake by human serotonin transporter in JAR cells, IC50=0.0324μM	15239661
K562	Cytotoxicity assay		Cytotoxicity to reduce chronic myeloid leukemia K 562 cells, CC50=25μM	15267229
U937	Cytotoxicity assay		Cytotoxicity to reduce human histolytic lymphoma U937 cells, CC50=33.3μM	15267229
HEK293	Function assay		Inhibition of [3H]5-HT uptake at 5HT transporter expressed in HEK293 cells, IC50=0.016μM	16750359
HEK293	Function assay		Inhibition of DA transporter expressed in HEK293 cells, IC50=4.4μM	16750359
HEK293	Function assay		Inhibition of [3H]NA uptake at NA transporter expressed in HEK293 cells, IC50=5.2μM	16750359
HEK293	Function assay		Inhibition of [3H]5-HT reuptake at 5HT transporter in HEK293 cells, IC50=0.016μM	16750363
HEK293	Function assay		Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells, IC50=4.4μM	16750363
HEK293	Function assay		Inhibition of [3H]NA reuptake at NA transporter in HEK293 cells, IC50=5.2μM	16750363
Jar	Function assay		Inhibition of [3H]5-HT uptake at human 5-HT transporter expressed in Jar cells, IC50=0.0394μM	16854086
SK-N-MC	Function assay		Displacement of N-[3H]alpha-methylhistamine from human histamine H3 receptor expressed in SK-N-MC cells, Ki=7.3μM	17307358
CHO	Function assay		Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique, IC50=1.51356μM	18448342
HEK293	Function assay		Inhibition of serotonin uptake at human SERT in human HEK293 cells, IC50=0.047μM	18550369
HEK293	Function assay		Inhibition of norepinephrine uptake at human NET in human HEK293 cells, IC50=2μM	18550369
HEK293	Function assay		Inhibition of dopamine uptake at human DAT in human HEK293 cells, IC50=6μM	18550369
JAR	Function assay		Inhibition of 5HT uptake at human SERT expressed in human JAR cells, IC50=0.0094μM	18557608
HEK	Function assay		Inhibition of serotonin uptake at human SERT expressed in HEK cells, IC50=0.047μM	18667309
HEK	Function assay		Inhibition of norepinephrine uptake at human NET expressed in HEK cells, IC50=2μM	18667309
HEK	Function assay		Inhibition of dopamine uptake at human DAT expressed in HEK cells, IC50=6μM	18667309
JAR	Function assay		Inhibition of serotonin uptake at human SERT expressed in JAR cells, IC50=0.01μM	18771916
MDCK	Function assay		Inhibition of norepinephrine uptake at human NET expressed in MDCK cells, IC50=0.563μM	18771916
Jar	Function assay		Inhibition of 5-HT transporter-mediated [3H]5HT uptake in human Jar cells, IC50=0.0394μM	18834188
JAR	Function assay		Inhibition of serotonin uptake at human SERT expressed in JAR cells, IC50=0.0094μM	18951020
HEK293	Function assay		Displacement of [125I]RTI55 from human recombinant SERT expressed in HEK293 cells, Ki=0.0011μM	19014888
HEK293	Function assay		Inhibition of [3H]5HT from human recombinant SERT expressed in HEK293 cells, IC50=0.007μM	19014888
HEK293	Function assay		Inhibition of [3H]NE from human recombinant NET expressed in HEK293 cells, IC50=1.02μM	19014888
HEK293	Function assay		Displacement of [125I]RTI55 from human recombinant NET expressed in HEK293 cells, Ki=1.56μM	19014888
HEK293	Function assay		Displacement of [125I]RTI55 from human recombinant DAT expressed in HEK293 cells, Ki=6.67μM	19014888
HEK293	Function assay		Inhibition of [3H]DA from human recombinant DAT expressed in HEK293 cells, IC50=19.5μM	19014888
HEK293	Function assay		Displacement of [125I]RTI-55 from human recombinant SERT expressed in HEK293 cells by scintillation counting, Ki=0.0011μM	19256502
HEK293	Function assay		Displacement of [3H]serotonin from human recombinant SERT expressed in HEK293 cells by scintillation counting, IC50=0.0073μM	19256502
HEK293	Function assay		Displacement of [3H]norepinephrine from human recombinant NET expressed in HEK293 cells by scintillation counting, IC50=1.02μM	19256502
HEK293	Function assay		Displacement of [125I]RTI-55 from human recombinant NET expressed in HEK293 cells by scintillation counting, Ki=1.56μM	19256502
HEK293	Function assay		Displacement of [125I]RTI-55 from human recombinant DAT expressed in HEK293 cells by scintillation counting, Ki=6.67μM	19256502
HEK293	Function assay		Displacement of [3H]dopamine from human recombinant DAT expressed in HEK293 cells by scintillation counting, IC50=19.5μM	19256502
JAR	Function assay		Inhibition of serotonin uptake at human SERT expressed in human JAR cells, IC50=0.01μM	19329313
MDCK-Net6	Function assay		Inhibition of norepinephrine uptake at human NET expressed in MDCK-Net6 cells, IC50=0.563μM	19329313
JAR	Function assay		Inhibition of serotonin uptake at human SERT expressed in JAR cells, IC50=0.0094μM	19632110
JAR	Function assay		Inhibition of human SERT expressed in JAR cells, IC50=0.0094μM	19713106
JAR	Function assay		Inhibition of [3H]hydroxytryptamine creatinine sulfate uptake at human SERT expressed in human JAR cells, IC50=0.0094μM	19722525
HEK293	Function assay		Displacement of [I125]RTI-55 from human SERT transfected in human HEK293 cells, IC50=0.0025μM	20034793
JAR	Function assay		Inhibition of serotonin uptake at human SERT expressed in human JAR cells, IC50=0.0094μM	20131864
JAR	Function assay		Inhibition of human SERT expressed in human JAR cells, IC50=0.0094μM	20378347
JAR	Function assay		Inhibition of SERT-mediated serotonin uptake in human JAR cells, IC50=0.0094μM	20462211
BESM	Antitrypanosomal assay	88 hrs	Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay, EC50=7μM	20547819
BESM	Cytotoxicity assay	88 hrs	Cytotoxicity against BESM cells after 88 hrs by HTS assay, EC50=16μM	20547819
HEK293	Function assay		Displacement of [3H] astemizole from human recombinant ERG channel expressed in HEK293 cells, IC50=3.1μM	20637635
HEK293	Function assay		Inhibition of serotonin reuptake at human SERT expressed in HEK293 cells, IC50=0.0031μM	20724153
HEK293	Function assay		Inhibition of [3H]serotonin reuptake at human SERT expressed in HEK293 cells by scintillation counting, IC50=0.0052μM	21093273
LLC-PK1	Function assay		Inhibition of [3H]serotonin reuptake at human recombinant SERT expressed in LLC-PK1 cells by liquid scintillation counting, IC50=0.005012μM	21310612
HEK293	Function assay		Inhibition of serotonin reuptake at SERT expressed in HEK293 cells, IC50=0.005012μM	21739935
JAR	Function assay		Inhibition of human SERT expressed in JAR cells assessed as serotonin uptake, IC50=0.0094μM	21916421
HEK293	Function assay		Inhibition of human SERT-mediated serotonin reuptake in HEK293 cells, EC50=0.0027μM	21927645
CHO	Function assay		Inhibition of rat voltage-gated K channel 3.1 expressed in CHO cells by patch clamp assay, IC50=13.1μM	23121096
HEK293	Function assay	60 mins	Displacement of [3H]Paroxetine from human recombinant SERT expressed in HEK293 cells after 60 mins, Ki=0.0014μM	23403082
HEK293	Function assay	60 mins	Displacement of [3H]Paroxetine from human recombinant SERT expressed in HEK293 cells after 60 mins, IC50=0.0086μM	23403082
HEK293	Function assay	10 mins	Inhibition of [3H]5-HT uptake at human SERT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay, Ki=0.098μM	23602445
HEK293	Function assay	10 mins	Inhibition of [3H]5-HT uptake at human SERT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay, IC50=0.28184μM	23602445
HEK293	Function assay	10 mins	Inhibition of [3H]norepinephrine uptake at human NET expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay, Ki=1.394μM	23602445
HEK293	Function assay	10 mins	Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay, Ki=3.764μM	23602445
HEK293	Function assay	10 mins	Inhibition of [3H]norepinephrine uptake at human NET expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay, IC50=6.30957μM	23602445
HEK293	Function assay	10 mins	Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay, IC50=9.12011μM	23602445
HEK293	Function assay		Displacement of [3H]imipramin from human recombinant SERT over-expressed in HEK293 cells, IC50=0.0072μM	24012181
HEK293	Function assay	15 mins	Inhibition of serotonin reuptake at human SERT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay, IC50=0.15μM	24974340
HEK293	Function assay	15 mins	Inhibition of norepinephrine reuptake at human NET expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay, IC50=4.41μM	24974340
HEK293	Function assay	15 mins	Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay, IC50=18.4μM	24974340
HEK293	Function assay	15 mins	Inhibition of human SERT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay, IC50=0.15μM	25221656
HEK293	Function assay	15 mins	Inhibition of human NET expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay, IC50=4.41μM	25221656
HEK293	Function assay	15 mins	Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay, IC50=18.4μM	25221656
HEK293	Function assay		Inhibition of of human TREK1 expressed in HEK293 cells assessed as reduction in channel currents, IC50=14μM	26588045
tsA201	Function assay		Inhibition of of human TREK1 expressed in tsA201 cells assessed as reduction in channel currents, IC50=19μM	26588045
OHS-50	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
MG 63 (6-TG R)	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	29435139
RD	Antiviral assay	5 mins	Antiviral activity against Enterovirus D68 US/KY/14-18953 infected in human RD cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 mins under shaking condition and measured after 3 days by neutral red dye-based photometric meth, EC50=1μM	30912944
RD	Cytotoxicity assay	3 days	Cytotoxicity against human RD cells after 3 days by neutral red dye-based photometric method, CC50=11.9μM	30912944
Huh7	Antiviral assay		Antiviral activity against DENV2 infected in human Huh7 cells by qRT-PCR analysis, IC50=0.38μM	31128447
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 69 mg/mL (199.54 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 69 mg/mL

Ethanol : 69 mg/mL

DMSO : 69 mg/mL (199.54 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 69 mg/mL

Water : 25 mg/mL (超声加热五分钟)

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	345.79	Formula	C₁₇H₁₈F₃NO.HCl	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	56296-78-7	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Lilly 110140 HCl, LY-110140 HCl			Smiles	CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F.Cl

Mechanism of Action

Targets/IC₅₀/Ki	5-HT
In vitro	Fluoxetine blocks the downregulation of cell proliferation resulting from inescapable shock (IS) of hippocampal cell. Fluoxetine increases the number of newborn cells in the dentate gyrus of the hippocampus of adult rat. Fluoxetine also increases the number of proliferating cells in the prelimbic cortex. Fluoxetine accelerates the maturation of immature neurons. Fluoxetine enhances neurogenesis-dependent long-term potentiation (LTP) in the dentate gyrus. Fluoxetine, but not citalopram, fluvoxamine, paroxetine and sertraline, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Fluoxetine produces robust and sustained increases in extracellular concentrations of norepinephrine and dopamine after acute systemic administration.
In vivo	Fluoxetine treatment also reverses the deficit in escape latency observed in animals exposed to inescapable shock in adult male Sprague–Dawley rats. Fluoxetine combined with Olanzapine produces robust, sustained increases of extracellular levels of dopamine ([DA](ex)) and norepinephrine ([NE](ex)) up to 361% and 272% of the baseline, respectively, which are significantly greater than either drug alone.
References	[1] https://pubmed.ncbi.nlm.nih.gov/12838272/ [2] https://pubmed.ncbi.nlm.nih.gov/15476686/ [3] https://pubmed.ncbi.nlm.nih.gov/18256257/ [4] https://pubmed.ncbi.nlm.nih.gov/11919662/ [5] https://pubmed.ncbi.nlm.nih.gov/10942849/ [6] https://pubmed.ncbi.nlm.nih.gov/33441923/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05634707	Recruiting	Primary Brain Tumor\|Brain Tumor Recurrent	Duke University	August 5 2023	Early Phase 1
NCT04676139	Unknown status	Nocturnal Enuresis	Mansoura University	July 1 2020	Phase 3
NCT01615055	Withdrawn	Cognitive Dysfunction	University of California Los Angeles\|City of Hope Medical Center	June 2018	Early Phase 1
NCT03390933	Completed	Depression\|Hemodialysis-Induced Symptom	MetroHealth Medical Center	March 1 2018	Phase 4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):